Illumina said this week that it has appointed Daniel Grosu as Chief Medical Officer, a newly created position at the company.
Grosu will play a key role in building Illumina’s diagnostic capabilities through collaborations with regulatory agencies, internal product development teams, and Illumina’s CLIA-certified clinical laboratory, the company said.
Prior to joining Illumina, Grosu was group director of clinical science and clinical and medical affairs at Ortho-Clinical Diagnostics. He was also previously the director and leader of global clinical development and diagnostic imaging at Bayer Healthcare Pharmaceuticals. Grosu has also worked for Siemens Medical Solutions. He holds a BS and MS degree from Wheaton College; an MD from Saint Louis University; and an MBA from the University of Oxford.
GeneNews said this week that it has appointed Karl Wassmann to the newly created position of executive vice president of US corporate development.
In his new role, Wassmann will manage GeneNews' SentinelGx services. Most recently he served as president and CEO of Source MDx, a privately-held U.S. company focused on the development of whole blood and rare cell-based inflammation and oncology biomarkers for laboratory developed tests and companion diagnostics. Wassmann has led more than 30 biomarker and companion diagnostic prospective clinical development programs totaling over 7,000 patients in collaboration with leading pharmaceutical companies and major academic medical centers, GeneNews said. He holds an MBA from the University of Chicago's Booth School of Business.